It’s only fair to share… Brezivaptan CAS 1370444-22-6 ANC-501, THY-1773, TS-121, 575OB1CKN0 MF C25H30ClN5O3 MW 484.0 g/mol 2-[3-(3-chlorophenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]-N-(propan-2-yl)acetamide 2-[3-(3-chlorophenyl)-1-[4-(2-morpholin-4-ylethyl)phenyl]-5-oxo-1,2,4-triazol-4-yl]-N-propan-2-ylacetamidevasopressin receptor antagonist Brezivaptan[1] (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[2][3][4] As of November 2022, it is in phase II clinical trials for this indication.[2][3][5] ANC-501 is under investigation in clinical trial NCT05439603 (ANC-501 in the Treatment …